| Required output | What can be stated from seed | What is missing without full text | Verification action |
|---|---|---|---|
| 1. Executive judgment | Provisional judgment: partially supported; seed PMIDs align with biallelic SYCE1-related meiotic failure in POI and NOA | Strength of evidence, exact cohort breadth, and whether support should be upgraded/downgraded after full review | Read all seed PMIDs in full; confirm whether human and functional data independently support each step |
| 2. Evidence matrix | Four seed sources cover human genetics (25062452), mouse model (32402064), interaction/functional data (34718620), and male histology/CNVs (35718780) | Exact methods, sample sizes, assay details, controls, and whether findings are primary or review-level | Extract study design, n, variant list, assays, figures, and limitations from each PMID |
| 3. Clinical spectrum summary | 46,XX: primary amenorrhea/POI; 46,XY: NOA with pachytene-stage arrest; testis H&E/IF mentioned in seed | Hormone values (FSH, AMH, LH, estradiol, testosterone), ovarian imaging, follicle depletion details, biopsy markers, ages | Check full text/tables for endocrine data, imaging, pathology wording, and karyotype details |
| 4. Variant and inheritance summary | Biallelic inheritance is implied; homozygous nonsense c.613C>T reported; CNVs and other damaging variants are mentioned | Exact zygosity of CNVs, segregation data, number of families, allele phasing, ACMG classification, carrier frequencies | Verify pedigrees, CNV breakpoints, inheritance/phase, and variant classification in full text and databases |
| 5. Mechanistic causal chain | Seed supports: SYCE1 loss/disrupted interaction with SYCP1 and C14ORF39/SIX6OS1 → SC assembly/synapsis defects → pachytene arrest → infertility | Direct evidence for each link in humans, checkpoint activation markers, apoptosis/germ-cell depletion assays, sex-specific mechanistic nuance | Review mechanistic figures and methods for SC staining, synapsis failure, checkpoint/apoptosis markers, and species differences |
| 6. Diagnostics and management implications | General implications can be inferred: include SYCE1 on infertility/POI panels; consider semen analysis, biopsy, endocrine workup, counseling | Disorder-specific management outcomes, fertility preservation success, micro-TESE yield, treatment response in reported cases | Check case reports/series for clinical management, reproductive outcomes, and recommendations tied to SYCE1 |
| 7. Ontology suggestions | Plausible labels: primary ovarian insufficiency, primary amenorrhea, azoospermia, spermatogenic arrest, synaptonemal complex assembly | Which labels are explicitly evidenced in patients/models versus inferred from meiotic biology | Map verified findings to HPO/GO/CL after full-text confirmation of phenotypes and mechanisms |
| 8. Knowledge gaps and weak claims | Human evidence appears limited; some mechanistic steps likely depend on mouse/in vitro inference; recent 2023-2024 updates were not retrieved | Whether additional cohorts exist, whether checkpoint/germ-cell depletion is directly shown in humans, and whether any claims are overstated | Search/update with PubMed/Scholar access; flag every human-vs-model distinction during curation |
| 9. Curation leads | Add leads for autosomal recessive SYCE1 LoF/CNV disease mechanism, dual-sex phenotype, and partner-interaction disruption | Curator-ready wording, exact evidence thresholds, and whether newer papers modify the entry | Manually verify seed PMIDs and any newer literature before promoting leads into the curated SYCE1 entry |


*Table: This table matches each requested report component to what can currently be said from the seed claims alone, what remains unresolved without full text, and the specific verification step needed. It is useful for converting the blocked literature-retrieval run into a curator action list.*